Table 3 Correlation with clinicopathologic characteristics of the patients and immunostaining of ANXA4 and FLNA (n = 94)

Gender

  Male

83

59(71.1)

0.455

57(68.7)

0.425

  Female

11

9(81.8)

5(45.5)

Age

  ≤40 yr

42

32(76.2)

0.453

28(66.7)

0.896

  >40 yr

52

36(69.2)

34(65.4)

T stage

  T1

8

3(37.5)

0.017^*

2(25)

0.042^*

  T2

44

29(65.9)

28(63.6)

  T3

36

30(83.3)

27(75)

  T4

6

6(100)

5(83.3)

N Stage

  N0

48

27(56.3)

0.001^*

38(79.2)

0.017^*

  N1

43

38(88.4)

23(53.5)

  N2

3

3(100)

1(33.3)

UICC Stage

  I

7

2(28.6)

0.004^*

4(57.1)

0.696

  II

31

19(61.3)

19(61.3)

  III

50

41(82)

34(68)

  IV

6

6(100)

5(83.3)

Diff.

  Well

80

59(73.8)

0.652

55(68.8)

0.180

  Moderate

10

6(60)

6(60)

  Poor

4

3(75)

1(25)

OSF Stage

  Early

27

22(81.5)

0.294

16(59.3)

0.278

  Moderated

46

30(65.2)

34(73.9)

  Advanced

21

16(76.2)

12(57.1)